13F Holdings
中文EN

ALEC Alector, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1653087 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY151.1%
TTM net income YoY138.4%
TTM EPS YoY134.0%
Revenue 3-yr CAGR21.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin20.2%
Net margin23.9%
FCF margin-86.5%
EBITDA margin22.6%

Returns

ROE47.5%
ROA16.5%
ROIC (approx.)217.2%
Asset turnover0.69x

Leverage & solvency

Liabilities / assets29.7%
Debt / equity0.00x
Current ratio4.10x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-3.62x
Accruals ratio76.4%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$162.87M$3.32M$1.05M$6.24M$3.26M$7.87M$3.67M$54.28M
R&D expense$30.03M$19.46M$17.86M$32.46M$29.35M$27.61M$33.64M$46.46M
SG&A expense$8.99M$8.25M$8.11M$13.34M$11.52M$14.40M$14.73M$15.03M
Operating income$123.84M-$24.39M-$24.92M-$39.57M-$37.61M-$34.14M-$44.70M-$7.25M
Pretax income$124.66M-$22.86M-$22.93M-$37.10M-$34.67M-$30.52M-$40.47M-$2.00M
Income tax$60,000$130,000$0$168,000$0$0$0$48,000
Net income$124.60M-$22.99M-$22.93M-$37.27M-$34.67M-$30.52M-$40.47M-$2.07M
EBITDA$124.82M-$23.34M-$23.84M-$38.40M-$36.37M-$31.81M-$43.71M-$6.01M
EPS (basic)1.11-0.21-0.21—-0.34-0.30-0.41—
EPS (diluted)1.11-0.21-0.21—-0.34-0.30-0.41—
Weighted avg. shares (diluted)112.48M111.22M110.59M—102.60M100.37M99.40M—
Balance sheet
Cash & equivalents$75.47M$59.91M$76.96M$65.80M$76.50M$44.77M$37.97M$34.87M
Short-term investments$63.23M$112.88M$129.55M$190.22M$214.60M$262.51M$316.58M$380.38M
Current assets$145.35M$180.09M$215.08M$266.45M$300.38M$319.18M$366.65M$424.82M
PP&E, net$7.66M$8.91M$9.93M$10.84M$12.71M$13.91M$16.21M$17.14M
Total assets$165.78M$202.85M$239.92M$293.24M$335.29M$356.42M$408.30M$468.30M
Current liabilities$35.41M$34.24M$40.97M$69.50M$79.96M$84.35M$109.77M$125.06M
Short-term debt$0$9.85M$1.48M$366,000———$0
Long-term debt$0$0$8.29M$9.32M$9.61M$9.54M$9.46M$9.39M
Total debt$0$9.85M$9.77M$9.69M$9.61M$9.54M$9.46M$9.39M
Total liabilities$49.21M$212.82M$229.53M$262.59M$277.57M$285.25M$313.69M$341.50M
Shareholders' equity$116.57M-$9.97M$10.38M$30.65M$57.71M$71.17M$94.61M$126.80M
Net debt-$75.47M-$50.07M-$67.19M-$56.11M-$66.89M-$35.23M-$28.51M-$25.48M
Shares outstanding112.27M111.66M111.03M110.36M107.45M101.21M99.99M99.09M
Cash flow statement
Operating cash flow-$24.15M-$34.22M-$49.81M-$41.69M-$32.51M-$49.05M-$60.78M-$55.03M
Capital expenditure$0$31,000$118,000$0$11,000$10,000$20,000$173,000
Free cash flow-$24.15M-$34.25M-$49.93M-$41.69M-$32.52M-$49.06M-$60.80M-$55.20M
Investing cash flow$50.09M$17.12M$60.95M$25.60M$49.54M$55.72M$65.73M$41.40M
Financing cash flow-$10.38M$50,000$25,000$5.39M$14.70M$122,000$0$9.79M
Depreciation & amortization$981,000$1.05M$1.08M$1.17M$1.24M$2.33M$984,000$1.24M
Stock-based compensation$2.00M$2.61M$2.91M$4.84M$6.40M$7.06M$8.35M$10.21M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.